回肠造口对晚期卵巢癌肿瘤减灭术后肾功能的不良影响
这项回顾性多机构研究纳入2013年4月至2022年3月日本五家机构中接受初次或间歇性肿瘤减灭术联合直肠切除的II-IV期卵巢癌患者215例,其中87例(40.5%)行回肠造口。回肠造口患者从化疗第一周期至辅助化疗后12个月估算肾小球滤过率更低(p<0.0001),辅助化疗后12个月慢性肾脏病发生率更高(p<0.0001)。年龄(p=0.039)、基线肾功能不全(p=0.013)和回肠造口(p<0.001)是辅助化疗后12个月慢性肾脏病的独立危险因素,造口关闭后估算肾小球滤过率未改善。
要点
- 回肠造口患者从化疗第一周期至辅助化疗后12个月估算肾小球滤过率更低(p<0.0001)。
- 回肠造口患者辅助化疗后12个月慢性肾脏病发生率更高(p<0.0001)。
- 造口关闭后估算肾小球滤过率未改善。
核心结论
- 在卵巢癌患者中,回肠造口可损害辅助化疗后的肾功能,且该影响在造口关闭后仍持续存在。
研究设计与样本
- 回顾性多机构研究,纳入2013年4月至2022年3月日本五家机构中诊断为II-IV期卵巢癌并接受初次或间歇性肿瘤减灭术联合直肠切除的患者215例,其中87例(40.5%)行回肠造口。
主要发现
- 回肠造口患者从化疗第一周期至辅助化疗后12个月估算肾小球滤过率低于无回肠造口患者(p<0.0001)。
- 回肠造口患者辅助化疗后12个月慢性肾脏病发生率高于无回肠造口患者(p<0.0001)。
- 逻辑回归分析显示年龄(p=0.039)、基线肾功能不全(p=0.013)和回肠造口(p<0.001)是辅助化疗后12个月慢性肾脏病的独立危险因素。
- 造口关闭未导致估算肾小球滤过率改善。
- 在回肠造口患者中,高造口输出量(>1500 mL/天)与辅助化疗后12个月慢性肾脏病发生独立相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to investigate the impact of ileostomy on both short- and long-term renal function in patients with advanced ovarian cancer. METHODS: This retrospective, multi-institutional study included patients diagnosed with stage II-IV ovarian cancer who underwent primary or interval debulking surgery with rectal resection at five institutions in Japan between April 2013 and March 2022. We assessed renal function during and up to 12 months following postoperative adjuvant chemotherapy (AC), using estimated glomerular filtration rate (eGFR) values and the incidence of chronic kidney disease (CKD) in patients with or without ileostomy. RESULTS: A total of 215 patients were included in the study, of whom 87 patients (40.5 %) underwent ileostomy. When comparing patients with and without ileostomy, those with ileostomy had a lower eGFR from the first cycle of chemotherapy up to 12 months after AC (p < 0.0001). Additionally, patients who underwent ileostomy were more likely to develop CKD 12 months after AC (p < 0.0001). Logistic regression analysis identified age (p = 0.039), baseline renal dysfunction (p = 0.013), and ileostomy (p < 0.001) as independent risk factors for CKD at 12 months after AC. Furthermore, stoma closure did not result in an improvement in eGFR. In patients who underwent ileostomy, high stoma output (>1500 mL/day) was independently associated with CKD development at 12 months after AC. CONCLUSIONS: In patients with ovarian cancer, ileostomy can impair renal function following AC, and this effect persists even after stoma closure.
引用
- Koike Y, Fujiwara A, Seki T, et al. The detrimental impact of diverting ileostomy on renal function after tumor debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2025. PMID: 40674826. doi:10.1016/j.ygyno.2025.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。